Trials / Completed
CompletedNCT02896413
The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Yonsei University · Academic / Other
- Sex
- Female
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Surgical stress and anesthesia may cause immunosuppression in immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor immunity. Dexmedetomidine has sympatholytic effect and preserves NK cell function. This study investigate the effect of dexmedetomidine on immune suppression and postoperative outcomes in patients undergoing uterine cancer resection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexmedetomidine group | dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery |
| DRUG | Control group | 0.9% saline infusion |
Timeline
- Start date
- 2016-06-02
- Primary completion
- 2018-10-24
- Completion
- 2018-10-24
- First posted
- 2016-09-12
- Last updated
- 2021-05-04
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02896413. Inclusion in this directory is not an endorsement.